EDAP TMS Continues Ablatherm-HIFU Leadership at AUA
June 03 2005 - 11:04AM
PR Newswire (US)
EDAP TMS Continues Ablatherm-HIFU Leadership at AUA Company to
Present at June 2005 6th International Consultation on New
Developments in Prostate Cancer and Prostate Disease and BAUS
Conferences LYON, France, June 3 /PRNewswire-FirstCall/ -- EDAP TMS
S.A. (NASDAQ:EDAP), is pleased to report successful continuation of
its education efforts relating to the advancement of HIFU
technology in combating prostate cancer at the American Urology
Association (A.U.A.) meeting, held May 24-27, in San Antonio,
Texas. The annual event gathered more than 6,000 attendees from the
urology field. Three abstracts relating to the efficacy of HIFU as
a treatment option were presented by Ablatherm-HIFU users Dr.
Albert Gelet, Dr. Stefan Thueroff and Pr. Christian Chaussy. * Dr.
Gelet, from Edouard Herriot Hospital, Lyon, presented an abstract
entitled "Prostate Cancer Control with Transrectal HIFU in 230
Patients: Five-Year Results," outlining an 86 percent success rate
and substantially lower side effect rates upon treatment
standardization within the clinical setting. Primary side effects
included incontinence falling from 28 percent to 9 percent and
bladder neck stenosis falling from 31 percent to 6 percent upon
standardization during the five-year study. Additionally, Gelet's
results indicate treatment repeatability of this option remains a
unique advantage as compared to alternative treatments. * Dr.
Thueroff, from Harlaching Hospital, Munich, presented the "Efficacy
of Local High Intensity Focused Ultrasound (HIFU) in Localized
Prostate Cancer," reporting results of more than 1,000 treatments
at a single center confirming high efficacy -- up to 93 percent as
measured by negative biopsies -- and low side effects on three
classes of patients including high-, medium and low-risk groups. *
Pr. Chaussy, from Harlaching Hospital, presented a prospective
study "Side Effects of Transrectal High Intensity Focused
Ultrasound (HIFU) in the Local Treatment of Prostate Cancer at 8
Years," showing the low side effects of local Ablatherm-HIFU in
primary cases and proving that these minimal side effects can be
sustained over the years. During that meeting, EDAP organized
specific daily "Meet the Experts" workshops inviting American
urologists to attend sessions moderated by Pr. Chaussy and Dr.
D'Hont, from A.Z. Middelheim, Antwerp, Belgium. At these workshops
both Dr. Gelet and Dr. Thueroff shared their experiences with
Ablatherm-HIFU on patients suffering radiotherapy failures and on
the five- year results, respectively. Attendees showed great
interest and enthusiasm for Ablatherm-HIFU technology. Also during
the AUA conference EDAP introduced the North American market to its
newest enhancement to Ablatherm-HIFU, the integrated imaging
system. This innovative probe allows users to obtain a high quality
3-D image while simultaneously treating. This significantly
shortens treatment time and offers increased imaging capability to
further refine treatment parameters -- a key contributor to patient
outcomes -- while continuing to lower the incidence of side
effects. Hugues de Bantel, CEO of EDAP, commented: "Our
participation in the AUA conference continues to demonstrate EDAP's
leadership role in the development and application of HIFU
technology to prostate cancer. Additionally, interest is growing in
the North American market for access to Ablatherm-HIFU as a
treatment alternative to more invasive traditional therapies which
also have higher side effects and are more disruptive to the
patient's lifestyle. The specific focus of the treatment combined
with proven successful results during long-term studies carried out
at multiple centers clearly shows HIFU will be a focal point of
future treatment in combating prostate cancer. EDAP is pleased to
be recognized as the world leader in the application of HIFU
technology to prostate cancer." EDAP will also be participating in
the 6th International Consultation on New Developments in Prostate
Cancer and Prostate Diseases, co-sponsored by the International
Union Against Cancer, to be held in Paris June 24-27. The event
will be assessing new trends in the fast developing area of
research against cancer. Pr. Guy Vallancien, from Institut
Mutualiste Monsouris, Paris, will be reviewing all existing
techniques for the treatment of prostate cancer and present a video
session titled "Ablatherm-HIFU for Localized Prostate Cancer: The
Minimally Invasive Alternative for Urologists" as part of EDAP's
continuing efforts to educate the broad urological community about
leading- edge Ablatherm-HIFU treatment. This presentation will be
followed by an interactive question and answer session. EDAP
invites all interested urologists to attend this session and
inquire about Ablatherm-HIFU. Finally, EDAP will be present at the
B.A.U.S. (British Association of Urology Surgeons) meeting to be
held in Glasgow, Scotland, from June 27 to July 1, 2005. The
company announced on April 1, 2005 the U.K. National Institute for
Clinical Excellence (NICE) approval of guidelines supporting the
use of High Intensity Focused Ultrasound (HIFU) for the treatment
of localized prostate cancer. The company is continuing to position
itself to reach a broader portion of the U.K. population through
expansion of its clinical partners and physician and patient
education. EDAP has been treating U.K. patients for more than a
year from its launch clinic at Stepping Hill Hospital in Stockport
under the direction of Dr. Stephen Brown. "EDAP continues to break
down barriers of education and visibility in the use of
Ablatherm-HIFU technology as the preferred treatment for prostate
cancer," de Bantel commented. "We continue to make significant
progress on multiple fronts in making this treatment more
accessible to both patients and urologists by gaining regulatory
approvals, continuing to work toward appropriate reimbursement and
providing innovative business models tailored to the needs of local
clinics so they can offer this highly effective treatment to their
patient population." About EDAP TMS S.A. EDAP TMS S.A. develops and
markets Ablatherm, the most advanced and clinically proven choice
for High Intensity Focused Ultrasound (HIFU) treatment of localized
prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side
effects. The company is also developing this technology for the
treatment of certain other types of tumors. EDAP TMS S.A. also
produces and commercializes medical equipment for treatment of
urinary tract stones using Extra-corporeal Shockwave Lithotripsy
(ESWL). For more information on the Company, contact the Investor
Relations Dept by phone at +33 (0)4 78 26 40 46 or see the
Company's Web site at: http://www.edap-tms.com/ . This press
release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties.
These include statements regarding the Company's growth and
expansion plans. Such statements are based on management's current
expectations and are subject to a number of uncertainties and risks
that could cause actual results to differ materially from those
described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described
in the Company's filings with the Securities and Exchange
Commission. CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe
Chauveau Blandine Confort +33 4 78 26 40 46 Halliburton Investor
Relations Matt Kreps - Geralyn DeBusk 972 458 8000 DATASOURCE: EDAP
TMS S.A. CONTACT: Hugues de Bantel, Philippe Chauveau, or Blandine
Confort, all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps or
Geralyn DeBusk, both of Halliburton Investor Relations,
+1-972-458-8000, for EDAP TMS S.A. Web site:
http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024